Navigation Links
China-Biotics, Inc. Begins Trial Production at New Facility, Affirms 2010 Revenue Guidance
Date:10/28/2009

SHANGHAI, Oct. 28 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics", "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today provided an update on its business.

The Company added eight new bulk additive customers in September and October, bringing its total number of bulk additive customers to 24. The newly signed customers are mainly engaged in manufacture of dairy, nutritional supplement, and animal feed products. The trial production of Phase I has recently begun at its new state-of-the-art production facility in Qing Pu Industrial Park in Shanghai. Phase I has a production capacity of 150 metric tons of probiotics per year.

"We are delighted to begin trial production at our new facility and start the second phase of our capacity expansion, which we expect to complete by the end of the year," said Mr. Jinan Song, China-Biotics' Chairman and Chief Executive Officer. "We continue to experience significant demand for our probiotics products and our pipeline of potential new bulk additive customers remains strong. As a result, we expect to achieve revenue growth of at least 50% during the 2010 fiscal year."

The Company has strengthened it senior management team to support operations at the new facility with the addition of Mr. Bin Li, vice general manager of manufacturing and Dr. Xiaoping Zhang, deputy director of R&D center. Mr. Li brings knowledge and expertise in dairy and yogurt production, having previously served as general manager of Yili Group Beijing Branch. Dr. Zhang has substantial expertise in application of probiotics, having previously served as senior R&D manager in Mengniu Dairy (Beijing) Co., Ltd. Yili Group and Mengniu Dairy are among China's top three dairy producers.

About China-Biotics, Inc.

China-Biotics, Inc., a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements. Through its wholly owned subsidiary, Shanghai Shining Biotechnology Co., Ltd., the Company has operations in Shanghai. Its proprietary product portfolio contains live microbial nutritional supplements under the "Shining" brand. Currently, the products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang. China-Biotics plans to launch 300 Shining brand retail outlets in major cities in China. Currently, China-Biotics is strategically expanding its production capacity of probiotics to meet growing demand in the bulk additive market. For more information, please visit http://www.chn-biotics.com .

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors include, but are not limited to, the Company's ability to market existing and new products, and changes from anticipated levels of sales, future national or regional economic and competitive conditions, market acceptance of its retail store concept, changes in relationships with customers, dependence on its flagship product profits and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    For more information, please contact:

     Eva Yan, CFO
     Email: evayan@chn-biotics.com
     Web:   htyp://www.chn-biotics.com


    CCG Investor Relations
     Crocker Coulson, President
     Phone: +1-646-213-1915 (New York)
     Email: crocker.coulson@ccgir.com
     Web:   http://www.ccgirasia.com

SOURCE China-Biotics, Inc.


'/>"/>
SOURCE China-Biotics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
2. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
3. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
4. Enrollment Begins on Human PK Study for Medidur(TM) FA
5. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
6. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
7. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
8. Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
9. DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug
10. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
11. Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... Los innovadores de COMBO[TM], ... introduce catéteres para la intervención de extremidades inferiores ... global especializada en el suministro de soluciones vasculares ... incluyendo productos para tratar la enfermedad arterial periférica. ... los dispositivos de primera entrada de la compañía ...
(Date:5/24/2016)... Een app die artsen over de hele ... behandelen, hun kennis kunnen delen en van elkaar kunnen ... revolutionaire MDLinking App, ontwikkeld door een internationale groep artsen ... en oncologisch chirurg dr. Gijs van Acker . ... dinsdag 24 mei officieel gepresenteerd op het Amsterdam Startup ...
(Date:5/23/2016)... 2016 Transparency Market Research has ... Insufficiency Market - Global Industry Analysis, Size, Share, Growth, ... the report, the exocrine pancreatic insufficiency market is anticipated ... to 2023 to reach US$2.85 Bn by 2023. ... by the deficiency of the exocrine pancreatic enzymes, causing ...
Breaking Medicine Technology:
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... MadgeTech will ... designed, engineered, and manufactured in Warner, New Hampshire at the MadgeTech headquarters. With products ... reliable monitoring solutions trusted by government agencies, including NASA. , In 2012, NASA ...
(Date:5/26/2016)... ARIZ. (PRWEB) , ... May 26, 2016 , ... An ... of American families. , The 550 employees of Sun Health Senior Living ... through Aetna that reduces their doctor and prescription copays for the year, while holding ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... supply chain solutions, today announced the organization has earned its ISO 13485 certification, ... and is compliant with all rules and policies associated with ISO quality standard ...
(Date:5/26/2016)... ... May 26, 2016 , ... North Cypress Medical Center ... Golf Club in Cypress. With the help of community partners, the event organizers raised ... renews hope for wounded service members and their families through health, wellness, and therapeutic ...
(Date:5/26/2016)... ... May 26, 2016 , ... The MIAMI Institute for Age Management ... Dr. Adonis Maiquez MD, ABAARM. Dr. Adonis , Wellness Physician of the MIAMI ... member of the Institute for Functional Medicine. , He also heads up FITTLab, the ...
Breaking Medicine News(10 mins):